Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Review Article
  • Published:

Review Article

Design of growth factor antagonists with antiangiogenic and antitumor properties

Abstract

This review describes our recent efforts in the development of novel therapies for cancer. Our primary approach is to design synthetic agents that antagonize the function of growth factors that are critically involved in oncogenesis and angiogenesis. We achieve this by designing synthetic molecules that can recognize the exterior surface of the growth factor and so block the interaction with its receptor tyrosine kinase. A key step is the construction of synthetic agents that contain a large (>400Å2) and functionalized surface area to recognize a complementary surface on the target growth factor. In the course of this work we have discovered a molecule, GFB-111, that binds to PDGF, prevents it from binding to its receptor tyrosine kinase, blocks PDGF-induced receptor autophosphorylation, activation of Erk1 and Erk2 kinases and DNA synthesis. The binding affinity for PDGF is high (IC50=250 nM) and selective over EGF, IGF-1, aFGF, bFGF and HRGβ. In nude mouse models GFB-111 also shows significant inhibition of tumor growth and angiogenesis.

This is a preview of subscription content, access via your institution

Access options

Rent or buy this article

Prices vary by article type

from$1.95

to$39.95

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3
Figure 4
Figure 12
Figure 5
Figure 6
Figure 7
Figure 8
Figure 9
Figure 10
Figure 11

Similar content being viewed by others

References

  • Anderson M, Ostman A, Kreysing J, Backstrom G, van de Poll M and Heldin C-H. . 1995 Growth Factors 12: 159–164.

  • Babine RE and Bender SL. . 1997 Chem. Rev. 97: 1359–1472.

  • Bach AC, Eyerman CJ, Gross JD, Bower MJ, Harlow RL, Weber PC and DeGrado WF. . 1994 J. Am. Chem. Soc. 116: 3207–3219.

  • Blaskovich MA, Lin Q, Delarue FL, Sun J, Park HS, Coppola D, Hamilton AD and Sebti SM. . 2000 Nature Biotechnology 18: 1065–1070.

  • Brandon C and Tooze J. . 1991 Introduction to Protein Structure, Garland: New York.

  • Campion SR and Niyogi SK. . 1994 Prog. Nucl. Acid Res. Mol. Biol. 49: 353–383.

  • Duan D, Pazin MJ, Fretto LJ and Williams LT. . 1991 J. Biol. Chem. 266: 413–418.

  • Engstom U, Engstrom A, Ernlund A, Werstermark B and Heldin C-H. . 1992 J. Biol. Chem. 267: 16581–16587.

  • Fenstermaker RA, Poptie E, Bonfield TL, Knauss TC, Corsillo L, Piskurich JF, Kaetzel CS, Jentoft JE, Gelfand C, DiCorleto PE and David M Kaetzel J. . 1993 J. Biol. Chem. 268: 10482–10489.

  • Fiona J and William GJ. . 1994 New Molecular Targets for Cancer Chemotherapy, Kerr DJ, Workman P Eds., CRC Press: Boca Raton 52.

  • Hamuro Y, Calama MC, Park HS and Hamilton AD. . 1997 Angew. Chemie Int. Ed. Engl. 36: 2680–2683.

  • Hart CE, Forstrom JW, Kelly JD, Seifert RA, Smith RA, Ross R, Murray MJ and Bowen-Pope DE. . 1988 Science 240: 1529–1531.

  • Hartwell LH, Szankasi P, Roberts CJ, Murray AW and Friend SH. . 1997 Science 278: 1064–1068.

  • Heldin C-H. . 1992 EMBO J. 11: 4251–4259.

  • Henriksen R, Funa K, Wilander E, Backstrom T, Ridderheim M and Oberg K. . 1993 Cancer Res. 53: 4550–4554.

  • Johnson A, Betsholtz C, von der Helm K, Heldin CH and Westermark B. . 1985 Proc. Natl. Acad. Sci. USA 82: 1721–1725.

  • LaRoclelle WJ, Pierce JH, May-Siroff M, Giese N and Aaronson SA. . 1992 J. Biol. Chem. 267: 17074–17077.

  • Middaugh CR, Mach H, Burke CJ, Volkin DB, Dabora JM, Tsai PK, Bruner MW, Ryan JA and Marfa KE. . 1992 Biochemistry 31: 9016–9024.

  • Muller YA, Li B, Christinger HW, Wells JA, Cunningham BC and de Vos AM. . 1997 Proc. Natl. Acad. Sci. USA 94: 7192–7197.

  • Oefner C, Arcy AD, Winkler FK, Eggimann B and Hosang M. . 1992 EMBO J. 11: 3921–3926.

  • Oefner C, Arey AD, Winkler FK, Eggimann B and Hosang M. . 1996 EMBO J. 11: 3921–3926.

  • Ostman A, Andersson M, Hellman U and Heldin C-H. . 1991 J. Biol. Chem. 266: 10073–10077.

  • Rockwell P and Goldstein NI. . 1995 Mol. Cell. Differ. 3: 315–335.

  • Sebti SM and Hamilton AD. . 2000 Expert Opinion On Investigational Drugs.

  • Seymour L, Dajee D and Bezwoda WR. . 1993 Breast Cancer Research and Treatment 26: 247–252.

  • Sun J, Blaskovich MA, Knowles D, Qian Y, Ohkanda J, Bailey RA, Hamilton AD and Sebti SM. . 1999 Cancer Res. 59: 4919–4926.

  • Thompson LD, Pantoliani MW and Springer BA. . 1994 Biochemistry 33: 3831–3840.

Download references

Acknowledgements

This work was supported by NIH PO1 CA78038-01A1 and United States Army grant DAMD17-99-1-9458.

Author information

Authors and Affiliations

Authors

Rights and permissions

Reprints and permissions

About this article

Cite this article

Sebti, S., Hamilton, A. Design of growth factor antagonists with antiangiogenic and antitumor properties. Oncogene 19, 6566–6573 (2000). https://doi.org/10.1038/sj.onc.1204121

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.onc.1204121

Keywords

This article is cited by

Search

Quick links